All In Biotech

Drug Trial Radar · NCT04180371

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

288

Planned (sponsor's estimate)

Start

Nov 7, 2019

Primary completion

Dec 31, 2026

Study completion Jul 31, 2027

Sponsor

Lead sponsor
BicycleTx LimitedIndustry
Sponsor type
Industry
First posted
Nov 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. * Learn more about BT5528 therapy alone and in combination with nivolumab.

Conditions

  • Advanced Solid Tumor Historically Known for High EphA2 Expression
  • Urothelial Cancer
  • Ovarian Cancer
  • Non-small Cell Lung Cancer
  • Head and Neck Cancer
  • Triple Negative Breast Cancer
  • Gastric/Upper Gastrointestinal Cancer

Interventions

  • BT5528Drug

    Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) or every other week (Days 1 and 15) on a 4-week cycle at the selected dose.

  • NivolumabDrug

    Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A-1 and A-2(escalations): Number of participants receiving BT5528 alone and in combination with nivolumab with treatment-emergent adverse eventsTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until 30 days post last dose
  2. Part A-1 and A-2 (escalations): Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities from BT5528 treatment alone and in combination with nivolumabTime frame: At the end of Cycle 1 (each cycle is 28 days)
  3. Part B: Objective response rate by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 tumor expression receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
  4. Part B: Duration of response by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
  5. Part B: Clinical benefit rate by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
  6. Part B: Time to tumor progression by RECIST 1.1 in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
  7. Part B: Progression-free survival by RECIST 1.1 in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks during study treatment)
  8. Part B: PFS at 6 months by RECIST 1.1 in participants with solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent (assessed every 8 weeks up to 6 months)
  9. Part B: Overall survival (OS) at 1 year in participants solid tumors historically known for high expression of EphA2 receiving BT5528 treatmentTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until death or loss of follow-up or withdrawal of consent

Locations

28 sites in 5 countries. Site status is shown where the registry gives one.

  • California Cancer Associates for Research and Excellence, Inc.

    Encinitas, California

  • University of California - Irvine Medical Center

    Orange, California

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado

  • Florida Cancer Specialists

    Sarasota, Florida

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    New York, New York

  • Stephenson Cancer Center (Oklahoma University)

    Oklahoma City, Oklahoma

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Sarah Cannon and HCA Research Institute

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Institut Jules Bordet

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Antwerp University Hospital (UZA)

    Edegem, Belgium

  • Universitair Ziekenhuis Gent (UZ)

    Ghent, Belgium

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Institut Catala d'Oncologia - L'Hospitalet

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Fundación Jimenez Diaz

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Centro Integral Oncologico Clara Campal

    Madrid, Spain

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • The Leeds Teaching Hospitals NHS Trust Of Trust Headquarters, St James's University Hospital

    Leeds, United Kingdom

  • Sir Bobby Robson Cancer Trials Research Centre, The Northern Center for Cancer Care, Freeman Hospital

    Newcastle upon Tyne, United Kingdom

  • Sarah Cannon Research Institute UK

    London, United Kingdom, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.